# **Original Article** The Impact of Portable High **Efficiency Hepa Filters on the Incidence of Invasive Fungal Infection in COVID 19 Inpatients in a Tertiary Care Hospital: A Retrospective Analysis from Pakistan**

Hepa Filters on the Incidence of **Invasive Fungal** Infection in COVID 19

### Aneera Ahmed<sup>1</sup>, Aiman Sultan<sup>2</sup>, Bushra Jamil<sup>2</sup>, Shobah Luxmi<sup>1</sup> and Tooba Khan<sup>3</sup>

### ABSTRACT

Objective: To identify impact of air filtration on incidence of Invasive fungal infections in COVID-19 patients after restructuring of COVID-19 wards.

Study Design: Cross-sectional observational study

Place and Duration of Study: This study was conducted at the Department of Clinical Microbiology and Infectious Disease at the COVID-19 ward from June 2021 to November 2021.

Materials and Methods: All COVID-19 patients >18 years (non-severe, severe and/or critical) admitted at the tertiary care center were included. Even COVID-19 patients with suspected IPA, based on isolation of fungal species from one or more respiratory samples were included. Two time frames were used for inclusion of patients, one three months prior to and second three months after installation of HEPA filters in COVID wards. Patients with underlying respiratory disease, previous history of invasive pulmonary aspergillosis, on chronic steroid use (>3 months), on broad-spectrum antibiotics and with hematological malignancies were excluded. SPSS version 23.0 was used for data analysis.

Results: From 187 patients, 97 enrolled before installation of HEPA filters while 90 after installation of HEPA filters. Overall the mean age of patients was  $62.7 \pm 14.6$  years. A significant difference of p-0.04 was observed in terms of length of stay in-between before installation of HEPA filter group (13.1  $\pm$  11.2 days) and in after installation of HEPA filter group (10.2  $\pm$  8.2 days). Beta-D-Glucan test with HEPA filter was positive in 17 (17.5%) of patients while in 28 (31.1%) of patients without HEPA filter (p-0.03). Treatment with Azoles was found to have significant difference in-between both groups (p-0.002). Overall, treatment was successful in 16 (16.5%) patients in without HEPA filter group while in 38 (42.2%) of patients with HEPA filter (p<0.001)

Conclusion: Substantial decrease in incidence of invasive fungal infections among COVID-19 patients was reported in terms of age, length of stay, Beta-D-Glucan, treatment with azoles and overall treatment in favor of HEPA filters. Key Words: HEPA filters, SARS-CoV-2, Invasive Fungal Infections.

#### Citation of article: Ahmed A, Sultan A, Jamil B, Luxmi S, Khan T. The Impact of Portable High Efficiency Hepa Filters on the Incidence of Invasive Fungal Infection in COVID 19 Inpatients in a Tertiary Care Hospital: A Retrospective Analysis From Pakistan. Med Forum 2023;34(5):124-128.

# **INTRODUCTION**

The primary spread of the global coronavirus (COVID-19) pandemic was due to airborne droplets.

<sup>1.</sup> Department of Infectious Diseases. National Institute of Cardiovascular Diseases, Karachi.

- <sup>2.</sup> Aga Khan University Hospital UGME, Karachi.
- <sup>3.</sup> Department of Pathology Baqai Medical College, Karachi.

Correspondence: Dr. Aneera Ahmed, Senior Registrar, National Institute of Cardiovascular Diseases, Department of Infectious Diseases. Contact No: 03012057139 Email: aneera.ahmed1@gmail.com

Received:	January, 2023
Accepted:	March, 2023
Printed:	May, 2023

To control the acquisition and/or transmission of such respiratory droplet infections is of prime importance, especially within indoor environments, where people remain in close contacts.<sup>1</sup> Reduction in airborne microbes can help in reducing not only respiratory but other systemic infections that can be transmitted through fomite or hand contamination and close contacts, through decrease in number of microbes which land on surfaces.<sup>2</sup>

In such circumstances, high specification filters are observed to cleanse air of droplets and aerosols.<sup>3</sup> Filtration of air is a commonly employed method for reducing infections especially in high-risk health care environments as in operation theatres and in hospital rooms for immune-compromised patients.4 Even portable air filtration units, were made initially for trapping vehicle emission particulates and pollen >0.02 micrometer, being more than sufficient for capturing droplets and aerosolized pathogens.<sup>5</sup> SARS-CoV 2 is around 0.1 micrometer in diameter.<sup>6</sup> A few products that are available commercially especially for domestic use include high efficiency particulate air (HEPA) filters, being capable of removing >99 % of aerosolized particles within a short amount of time.<sup>7</sup>

Various techniques have been used for preventing fungal infections especially in immune-compromised patients but have yielded limited effects; reducing environmental exposure though air-handling system specialized in being able to exclude fungal (Aspergillus specie).<sup>8</sup> For instance, by using HEPA filters either with or without ventilation (laminar air flow) it has been regarded as being highly efficacious, by augmenting natural defense mechanism of hosts through recombinant growth factors.<sup>9</sup>

Outbreaks of nosocomial invasive fungal infections such as aspergillosis have been reported within last couple of decades, being correlated with increase in air counts of Aspergillus specie.<sup>10</sup> To minimize such outbreaks, it is pivotal to control and manage the aerosolized environment for preventing contamination.<sup>11</sup> The mechanism by which filtration of aerosol particles take place in gas phase has been extensively studied, however the combined action of all such filtration mechanisms by using HEPA filters tends to show their high efficiency of filtering across the spectrum of aerosols.<sup>12</sup>

Despite advances and use of air filtration in healthcare environments as in operation theatres, yet it remains unresolved as to whether the effect of air filtration when deployed in other setting such as in wards will have the same effect or not.<sup>13,14</sup>

The objective of this study was to determine the impact of air filtration on incidence of fungal infections among COVID-19 patients after restructuring of COVID-19 wards using HEPA filters. A secondary objective was to identify incidence of invasive aspergillosis in COVID-19 patients prior to restructuring with air filtration, therefore evaluating the environmental effect on nosocomial fungal infection's incidence at a tertiary care center.

## MATERIALS AND METHODS

This cross sectional observational study was carried out for a period of 6 months, from June 2021 to November 2021 at the COVID-19 ward, Department of Clinical Microbiology and Infectious Disease where maintenance of surveillance and registry of fungal infections and an anti-fungal stewardship programme is done. This was a single-centered study with over 1500 beds in the hospital. Patients, above the age of 18 years. admitted due to COVID-19 (severe, non-severe and/or critical) where included in the study. In addition, COVID-19 patients with suspected invasive pulmonary aspergillosis (IPA) based on isolation of Aspergillus species from one or more respiratory sample were also included in the study. Patients with underlying lung disease, on chronic steroid use (>3 months) and with use of broad-spectrum of antibiotic (< 3 months) and with any hematological malignancy were excluded from the study.

### RESULTS

From the total of 187 patients included in the study, 97 were enrolled before installation of HEPA filters while 90 after installation of HEPA filters. Overall, the mean age of patients was  $62.7 \pm 14.6$  years. In patients before installation of HEPA filters, the mean age was 60.5  $\pm$ 14.2 years while in patients admitted after HEPA filter installation, the mean age was  $65.2 \pm 14.7$  years. A significant difference of p-0.03 was observed between the two groups. Overall, 100 (58.8%) patients were males while 77 (41.2%) females, in without HEPA filter group, 60 (61.9%) patients were male while 37 (38.1%) females whereas in HEPA filter group, 50 (55.6%) were males while 40 (44.4%) were females. having an insignificant difference of p-0.38 between them. A significant difference of p-0.04 was observed in terms of length of stay in-between before installation of HEPA filter group (13.1  $\pm$  11.2 days) and in after installation of HEPA filter group ( $10.2 \pm 8.2$  days).

The Beta-D-Glucan test in before installation of HEPA filter group was positive in 17 (17.5%) of patients while in 28 (31.1%) of patients after installation of HEPA filter, with a significant difference of p-0.03. A significant difference of p-0.04 was reported in terms of malignancy in-between patients included in both groups. Treatment with Azoles was found to have significant difference in-between both the groups (p-0.002). Overall, treatment was successful in 16 (16.5%) of patients in before installation of HEPA filter group while in 38 (42.2%) of patients after installation of HEPA filter (p<0.001) Table No. 1.

	Total (n=187)	Without Hepa-filter (n=97)	With Hepa-filter (n=90)	p-value
Age	$62.7 \pm 14.6$	$60.5 \pm 14.2$	$65.2 \pm 14.7$	0.03
Gender				
Male	110 (58.8)	60 (61.9)	50 (55.6)	0.38
Female	77 (41.2)	37 (38.1)	40 (44.4)	
Ward				

 Table No. 1: Cross tabulation of variables with versus without Hepa-Filter (n=187)

Med. Forum, Vol. 34, No. 5

126

Med. Forum, Vol. 34, No. 5	126			May, 2023	
P1	48 (25.7)	27 (27.8)	21 (23.3)		
P2	29 (15.5)	17 (17.5)	12 (13.3)		
Р3	92 (49.2)	42 (43.3)	50 (55.6)	0.45	
ACU	10 (5.4)	7 (7.2)	3 (3.3)		
ER	8 (4.3)	4 (4.1)	4 (4.4)		
Length of stay	$11.7\pm9.9$	$13.1 \pm 11.2$	$10.2 \pm 8.2$	0.04	
Beta-D-Glucan					
Negative	112 (59.9)	67 (69.1)	45 (50.0)		
Positive	45 (24.1)	17 (17.5)	28 (31.1)	0.03	
Not done	30 (16.0)	13 (13.4)	17 (18.9)		
GM					
Negative	112 (60.5)	60 (63.2)	52 (57.8)		
Positive	43 (23.3)	22 (23.2)	21 (23.2)	0.61	
Not done	17 (18.9)	13 (13.7)	17 (18.9)		
Diabetes mellitus	115 (61.5)	58 (59.8)	57 (63.3)	0.61	
Chronic kidney disease	21 (11.2)	8 (8.2)	13 (14.4)	0.18	
Hypertension	100 (53.5)	49 (50.5)	51 (56.7	0.40	
Ischemic heart disease	39 (20.9)	15 (15.5)	24 (26.7)	0.06	
Malignancy	11 (5.9)	9 (9.3)	2 (2.2)	0.04	
CVA	12 (6.4)	4 (4.1)	8 (8.9)	0.18	
Connective tissue disease	7 (3.7)	6 (6.2)	1 (1.1)	0.07	
Chronic pulmonary disease	26 (13.9)	17 (17.5)	9 (10.0)	0.14	
Azoles	128 (68.4)	76 (78.3)	47 (52.2)	0.002	
Ecchinocandins	9 (4.8)	7 (7.2)	2 (2.2)	0.11*	
AmphotericinB	29 (15.5)	16 (16.5)	13 (14.4)	0.70	
Treatment	54 (28.9)	16 (16.5)	38 (42.2)	< 0.001	
Duration of development of infection	4	4	3	0.35	
Тосі	46 (24.6)	30 (30.9)	16 (17.8)	0.04	
Clinical symptoms	126 (67.4)	69 (71.1)	57 (63.3)	0.26	
Radiological change	93 (49.7)	45 (46.4)	48 (53.3)	0.34	
Mortality	74 (39.6)	34 (35.1)	40 (44.4)	0.19	
•		Doubity of data mana	, ,		

### DISCUSSION

According to the results of this study of 187 patients with 97 admitted before installation of HEPA filters and 90 patients admitted after HEPA filters installation, it was observed that a significant reduction in the length of stay, positivity of Beta-D-Glucan test, treatment with Azoles, overall success after treatment and Tocilizumab with positive results in favor of HEPA filters. Even though clinical symptoms decreased from 71 % to 63 % after installation of HEPA filters, yet the mortality increased from 35 % in the pre-HEPA filter installation group to 44 % in the post-HEPA filter installation group. Positivity of Beta-D-Glucan decreased from 69 % in pre-HEPA filter group to 50 % in post-HEPA filter group. Likewise, the duration of infection development was although not significantly but slightly lesser in the HEPA filter group as compared to the without filter group.

Paucity of data persists in the published literature with regards to effectiveness of portable HEPA filters in being able to reduce incidences of infections of respiratory tract, including SARS-CoV-2 especially in indoor environments (15-17). In one of the research projects, it was observed that in comparing use of HEPA filter in immune-compromised patients, the frequency of respiratory fungal infections in patients with HEPA filter was reported to be 07 % (18/254) while 17 % (6/35) in the without filter groups. However, there was no difference in terms of 100-days mortality in-between the two groups (14 % vs. 17 %).<sup>18</sup> In yet another study aimed at determining the incidence of IPA after installation of HEPA filters, it was reported that in the group without HEPA filters, the average Aspergillus specie were observed at 15 spores/m<sup>3</sup> while in HEPA filter group, the average count of Aspergillus specie was reported at around 0.18 spores/m<sup>3</sup>. This showed that HEPA filters lead to substantial decrease in the air counts of fungal organisms, a finding also observed in our study as well.<sup>19</sup>

#### Med. Forum, Vol. 34, No. 5

From the above, it is evident that intervention that are based on filtration of air by using adequate equipment's must be widely implemented for reduction of spread of SARS-CoV-2 via aerosol phase as well as for preventing spread of invasive fungal infections.<sup>20</sup>

Although this study evaluated the factors associated with incidence of IPA with or without HEPA filters, yet this study was not free from limitations. Since this study was a single centered study with limited sample size of 187 and was divided in two groups with variable demographics, the study was also not free from selection and observer bias. Further, multi-centered studies with greater sample size would be enlightening to generalize the findings reported in this study.

# CONCLUSION

According to the findings of this study, a substantial decrease in the incidence of invasive fungal infections among COVID-19 patients was reported in terms of age, length of stay, Beta-D-Glucan, treatment with azoles and overall, in favor of HEPA filters. Nonetheless mortality was found to have insignificant difference between both groups.

#### **Author's Contribution:**

Aneera Ahmed			
Aiman Sultan, Bushra			
Jamil			
Shobah Luxmi, Tooba			
Khan			
Aneera Ahmed, Aiman			
Sultan			
Aneera Ahmed			

**Conflict of Interest:** The study has no conflict of interest to declare by any author.

### REFERENCES

- 1. Morawska L, Milton DK. It is time to address airborne transmission of coronavirus disease 2019 (COVID-19). Clin Infec Diseases 2020; 71(9):2311-3.
- Conway Morris A, Sharrocks K, Bousfield R, Kermack L, Maes M, Higginson E, et al. The removal of airborne severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) and other microbial bioaerosols by air filtration on coronavirus disease 2019 (COVID-19) surge units. Clin Infectious Diseases 2022;75(1):e97-101.
- 3. Bluyssen PM, Ortiz M, Zhang D. The effect of a mobile HEPA filter system on 'infectious' aerosols, sound and air velocity in the SenseLab. Building and environment 2021;188:107475.

- Christopherson DA, Yao WC, Lu M, Vijayakumar R, Sedaghat AR. High-efficiency particulate air filters in the era of COVID-19: function and efficacy. Otolaryngol–Head and Neck Surg 2020;163(6):1153-5.
- 5. Sublett JL. Effectiveness of air filters and air cleaners in allergic respiratory diseases: a review of the recent literature. Current Allergy Asthma Reports 2011;11(5):395-402.
- Nazaroff WW. Indoor aerosol science aspects of SARS-CoV-2 transmission. Indoor Air 2022; 32(1):e12970.
- Mousavi ES, Kananizadeh N, Martinello RA, Sherman JD. COVID-19 outbreak and hospital air quality: a systematic review of evidence on air filtration and recirculation. Environmental Science Technol 2020;55(7):4134-47.
- Dailly S, Boatswain E, Brooks J, Campbell G, Dallow K, Dushianthan A, et al. Aspergillus in COVID-19 intensive care unit; what is lurking above your head? J Infect Prevention 2022; 23(6):278-84.
- 9. Elias B, Bar-Yam Y. Could air filtration reduce COVID-19 severity and spread. New England Complex Systems Institute 2020;9.
- Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. J Fungi 2021; 7(11):921-53.
- 11. Benge CD, Barwise JA. Aerosolization of COVID-19 and contamination risks during respiratory treatments. Federal Practitioner 2020;37(4):160-3.
- 12. Howard BE. High-risk aerosol-generating procedures in COVID-19: respiratory protective equipment considerations. Otolaryngol–Head Neck Surg 2020;163(1):98-103.
- 13. Al-Benna S. Negative pressure rooms and COVID-19. J Perioperative Practice 2021;31(1-2):18-23.
- 14. Silva PG, Gonçalves J, Lopes AI, Esteves NA, Bamba GE, Nascimento MS, et al. Evidence of Air and Surface Contamination with SARS-CoV-2 in a Major Hospital in Portugal. Int J Environmental Res Public Health 2022;19(1):525-37.
- 15. Fernández de Mera IG, Granda C, Villanueva F, Sánchez-Sánchez M, Moraga-Fernández A, et al. HEPA filters of portable air cleaners as a tool for the surveillance of SARS-CoV-2. Indoor Air 2022; 32(9):e13109.
- 16. Thuresson S, Fraenkel CJ, Sasinovich S, Soldemyr J, Widell A, Medstrand P, et al. Airborne severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in hospitals: effects of aerosol-generating procedures, HEPA-filtration units, patient viral load, and physical distance. Clin Infectious Diseases 2022;75(1):e89-96.

#### Med. Forum, Vol. 34, No. 5

- 17. Rhee C, Baker MA, Klompas M. Prevention of SARS-CoV-2 and respiratory viral infections in healthcare settings: current and emerging concepts. Current Opinion Infectious Diseases 2022; 35(4):353-62.
- 18. Vokurka S, Bystrická E, Svoboda T, Škoda Gorican IK, Sever M, Mazur E, et al. The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern E uropean study. J Clin Nursing 2014;23(11-12): 1648-52.
- 19. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001;66(4):257-62.
- Chiurlo M, Mastrangelo A, Ripa M, Scarpellini P. Invasive fungal infections in patients with COVID-19: A review on pathogenesis, epidemiology, clinical features, treatment, and outcomes. New Microbiol 2021;44(2):71-83.